A1AT Liver disease
Normal human A1AT is a 52-kDa glycoprotein of the serpin (serine proteinase inhibitor) family, predominantly produced in the liver and released into the blood.
In affected patients, circulating levels of mutant A1AT are ≤15% of normal protein levels.
A1ATD is unique in that it is a proteinopathy that impacts the lungs and the liver by different mechanisms [9].
In the lungs, it is a loss-of-function mutation, where A1AT is an inhibitor of neutrophil elastase. Emphysema results when A1AT is not present to inhibit the serine proteinase, allowing it to freely destroy the lung tissue [10].
The liver disease associated with A1ATD is a gain-of-toxic function mechanism. The misfolded insoluble globular proteins (ATZ) accumulate in the endoplasmic reticulum (ER), leading to hepatic fibrosis and even hepatocellular carcinoma (HCC) [11]
Liver transplant is the only curative treatment.
Comments
Post a Comment